日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension

一项综合分析纳入了四项观察性研究,旨在评估比马前列素0.01%滴眼液在原发性开角型青光眼或高眼压患者中的降眼压能力和耐受性。

Stevens, Annemie; Iliev, Milko E; de Jong, Leo; Grobeiu, Ioana; Hommer, Anton

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice

临床实践中,不含防腐剂的比马前列素0.03%/噻吗洛尔0.5%固定复方制剂用于治疗青光眼患者。

Pfennigsdorf, Stefan; Eschstruth, Peter; Häsemeyer, Stefan; Feuerhake, Cord; Brief, Gerrett; Grobeiu, Ioana; Shirlaw, Andrew